Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 15,000 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.58, for a total transaction of $608,700.00. Following the completion of the transaction, the chief executive officer now directly owns 1,302,987 shares of the company’s stock, valued at $52,875,212.46. This represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, January 8th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.85, for a total transaction of $732,750.00.
• On Wednesday, December 4th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.58, for a total transaction of $698,700.00.

Apogee Therapeutics Trading Down 4.6 %

Apogee Therapeutics stock opened at $39.72 on Friday. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -16.41 and a beta of 2.18. Apogee Therapeutics, Inc. has a 12 month low of $33.14 and a 12 month high of $72.29. The stock’s 50 day moving average is $44.25 and its 200-day moving average is $48.53.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.13). As a group, equities research analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apogee Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Apogee Therapeutics in the 3rd quarter worth about $71,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Apogee Therapeutics by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after purchasing an additional 285 shares during the period. Aigen Investment Management LP acquired a new stake in shares of Apogee Therapeutics in the fourth quarter valued at approximately $216,000. Wexford Capital LP bought a new stake in shares of Apogee Therapeutics in the third quarter valued at approximately $230,000. Finally, Arizona State Retirement System grew its position in Apogee Therapeutics by 17.3% during the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company’s stock worth $295,000 after buying an additional 960 shares in the last quarter. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on APGE shares. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, December 12th. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Finally, Wedbush increased their price target on Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics presently has an average rating of “Buy” and a consensus target price of $89.71.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.